Impact of Cipepofol versus Propofol on Long-Term Cardiovascular Outcomes After TAVR: An Extended Follow-Up of a Randomized Trial.
Tingting Ni, Yantian Lv, Laiying Zhou et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the long-term cardiovascular outcomes of cipepofol versus propofol in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) in a randomized controlled trial. At 1 year, the primary composite endpoint occurred in 22.0% of the cipepofol group compared to 37.3% in the propofol group (HR 0.56; P = 0.093), indicating a trend towards better outcomes with cipepofol.
Key findings
- The primary composite endpoint at 1 year was 22.0% for cipepofol vs 37.3% for propofol (HR 0.56; P = 0.093).
- New-onset atrial fibrillation occurred in 11.9% of the cipepofol group compared to 28.8% in the propofol group (HR 0.39; P = 0.037).
- At 30 days, the composite endpoint was 15.3% for cipepofol vs 23.7% for propofol (HR 0.63; P = 0.277).
- In-hospital composite endpoints were 16.4% for cipepofol vs 26.2% for propofol (P = 0.185).
Why it matters
Understanding the impact of anesthetic agents on long-term outcomes in TAVR patients is crucial, as it may influence anesthetic choice and management strategies to improve patient safety and reduce complications.
What to keep in mind
The study's findings are limited by a small sample size and the exploratory nature of the analysis, which may affect the robustness of the conclusions.